학술논문
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Document Type
Article
Author
Source
In The Lancet Oncology June 2022 23(6):768-780
Subject
Language
ISSN
1470-2045